Supplemental Statement - FARA

More documents

Recommendations

Info

Received by NSD/FARA Registration Unit 05/01/2012 4:09:43 PM GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery EDINBURGH, Scotland - GlaxoSmithKline (GSK) and the University of Edinburgh have agreed on a collaborative partnership to discover and develop medicines with the potential to treat severe acute pancreatitis. The alliance will build on work by university researchers that recently uncovered a molecular mechanism believed to have a major role in triggering iife-threatening multiple organ failure. The collaboration will integrate the deep biology and disease understanding ofthe academic group led by Damian Mole and Dr. Scott Webster the University's College of Medicine and Veterinary Medicine with GSK's expertise in drug discovery and development. "Despite treatment for severe acute pancreatitis, up to a quarter of people affected will die from an attack. By teaming up with GSK, we have the opportunity to turn our science into a medicine," said Mole. Webster added, "This is a great example of translating academic research. The alliance brings together our collective expertise in target biology and drug discovery to tackle an enormous unmet medical need." Work on the project will be carried out both within GSK and at the College of Medicine and Veterinary Medicine located at the Edinburgh BioQuarter (http://bit.ly/tfrXA7), Scotland's flagship life sciences development. Under the terms negotiated by the BioQuarter, the University will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialized out of the collaboration. This alliance comes through GSK's Discovery Partnerships with Academia (DPAc) team, a recently formed group designed to bring together the complementary skill sets of'.GSK'-a'rvdindividual academic groups in the search for innovative medicines. Dr. Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: "This collaborative partnership with a world-leader in drug discovery demonstrates the strength and depth of research being conducted, here in Edinburgh. We are delighted to have been selected as one of just ten DPAc projects being awarded globally by GlaxoSmithKline." About Edinburgh BioQuarter ### At the heart of Scottish life sciences, Edinburgh BioQuarter is a joint venture between Alexandria Real Estate Equities, Inc, the NHS, the University of Edinburgh and Scottish Enterprise. Edinburgh BioQuarter commercializes world-leading medical research and brings investors, ideas and companies together at the BioQuarter campus on the outskirts of Edinburgh. For more information, visit www.edinburghbioquarter.com Media Contact: Jordan Robinson, 212-725-0707, jordan.robinson(a)aboutdci.com Received by NSD/FARA Registration Unit 05/01/2012 4:09:43 PM
Received by NSD/FARA Registration Unit 05/01/2012 4:09:43 PM For Immediate Release Expanding Scottish biotech company Ingenza opens new tissue culture laboratory SCOTLAND (March 26, 2012) - Ingenza Ltd. based at the Roslin BioCentre has today celebrated the opening of a new tissue culture laboratory. The state-of-the-art clean room will expand the company's capabilities to construct efficient cell lines to produce human therapeutics and is complimentary to Ingenza's microbial strain construction expertise. Ingenza's staff has doubled in size every two years to date since the business began in 2003, as the company has applied its suite of biosciences enabling technologies to new sectors of UK industry. Ingenza is now primarily focussed in the strategic areas of biologies development and manufacture and the application of synthetic biology for sustainable bioprocessing. The company's customer base extends through Europe and North America in the areas of.pharma, chemicals, food,.feed arid renewable fuels. The new laboratory will create 4 new jobs within the first year and potentially 35 additional jobs within 3 years, augmenting the 25 current members of staff. President of ingenza, Dr. Ian Fotheringham explains, "Today illustrates Ingenza's potential to provide commercial and manufacturing support for Scotland's state-of-theart research in life sciences." Rhona Allison, Life Sciences Director at Scottish Enterprise, officially opened the new suite and said: "The opening of this impressive new laboratory marks an important milestone in the development of Ingenza's business in Scotland. The company has continued to go from strength to strength since moving to Roslin Biocentre and is a great example of Scotland's thriving life sciences sector. We look forward to continuing to work closely with the company to support its ambitious expansion plans." Ingenza were also joined by.local Cllr Russell Imrie, who explained; "Ingenza's involvement in a wide range of sectors, and its achievements as a synthetic biology SME are indicative of the growth of the science sector in Midlothian as •partof a strong_and diversified local economy of national and international importance. Midlothian Council recognizes this in the development ofthe Midlothian Economic Development Framework, arid the Life Sciences, Animal Biosciences and Earth Sciences sector action plans." : If you require further information about this release or for more information about Ingenza please contact Sarah Graham, Office and Public Relations Manger sarah.qrahamtainaenza.com Received by NSD/FARA Registration Unit 05/01/2012,- 4:09:43 PM ###
Page 1 and 2: Received by NSD/FARA Registration U
Page 13: Received by NSD/FARA Registration U
Page 23 and 24: AWeeBitofN&S 1 of 2 Having trouble
Page 39 and 40: ^.Received by NSD/FARA Registration
Page 41 and 42: deceived by NSD/FARA Registration U
Page 49 and 50: t=S Received by NSD/FARA Registrati
Page 51 and 52: Received by NSD/FARA Registration \
Page 53 and 54: eceived by NSD/FARA Registration Ur
Page 55 and 56: eceived bv NSD/FARA Registration Un
Page 57 and 58: i*m L.Ss eceived bv NSD/FARA Regist
Page 59 and 60: s«a •SWfc W ii Received by NSD/F
Page 61 and 62: eceived bv NSD/FARA Registration Un
Page 63 and 64: .Received by NSD/FARA Registration
Page 65 and 66:
•V-"V.,r ; •vW Received by NSD/
Page 67 and 68:
Received by NSD/FARA Registration U
Page 69 and 70:
eceived bv NSD/FARA Registration Un
Page 71 and 72:
i. ^vJ y )Mr, -**JWS> 4_fi!_Hfc *
Page 73 and 74:
-*r. eceived bv NSD/FARA Re istrati
Page 75 and 76:
eceived b NSD/FARA Registration IIn
Page 77 and 78:
Page 79 and 80:
•Received by NSD/FARA Registratio
Page 81 and 82:
l
Page 83 and 84:
eceived by NSD/FARA Registration Um
Page 85 and 86:
Leceived by NSD/FARA Registration U
Page 87 and 88:
_T
Page 89 and 90:
-Received by NSD/FARA Registration
Page 91 and 92:
Page 93 and 94:
mpHMip Received by NSD/FARA Registr
Page 95 and 96:
Page 97 and 98:
BE M eceived NSD/FARA Uni no 42 i M
Page 99 and 100:
Page 101 and 102:
^^^^Received by NSD/FARA Registrati
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Received by NSD/FARA Registtgjpn Un
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169:
show all

Supplemental Statement - FARA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?